Curis, Inc.

387 articles with Curis, Inc.

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 5, 2019

  7/5/2019

  Curis, Inc. announced that on July 1, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 238,000 shares of Curis common stock to four new employees, with a grant date of July 1, 2019.

• Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS

  6/12/2019

  Publication demonstrates specific U2AF1 splicing factor mutations induce oncogenic IRAK4-L isoform and activate innate immune pathways in myeloid malignancies

• Curis Reports First Quarter 2019 Financial Results

  5/14/2019

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2019

• Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

  5/7/2019

   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial results on Tuesday, May 14, 2019, after the close of US markets

• Curis Completes Mesothelioma Enrollment in CA-170 Study

  5/6/2019

  Curis, Inc. announced that the Phase 1 study of CA-170 has reached its target enrollment of mesothelioma patients.

• Curis Announces Advancement to the 200mg BID Cohort in the CA-4948 Study

  4/8/2019

  Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it has begun dosing patients in the 5th cohort (200mg BID; total daily dose of 400mg) in the Phase 1 trial of CA-4948, an orally available small molecule inhibitor of IRAK4, for treatment of patients with non-Hodgkin lymphoma,

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 5, 2019

  4/5/2019

  Curis, Inc. announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019.

• 

  Changing the Public’s Perception of the Biopharma Industry

  4/3/2019

  Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.

• Curis Reports Fourth Quarter and Year-End 2018 Financial Results

  3/26/2019

  Management to host conference call today at 4:30 p.m. ET

• Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

  3/25/2019

  Curis, Inc. announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets.

• Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

  3/25/2019

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.

• Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

  3/4/2019

  Curis, Inc. announced that James Dentzer, President and Chief Executive Officer, will present at the Cowen & Company 39th Annual Healthcare Conference on Wednesday, March 13th, at 11:20 a.m. – 11:50 a.m. EST in the Berkeley room at the Marriott Copley in Boston, MA.

• Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

  2/4/2019

  Curis, Inc. today announced that James Dentzer, President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference on Tuesday, February 12th, at 10:30 a.m. EST in the Hudson/Empire Room at the Marriott Marquis in New York City.

• First Mesothelioma Patient Dosed in CA-170 Study

  1/24/2019

  Curis, Inc. today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170.

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on January 4, 2019

  1/4/2019

  Curis, Inc. announced that on January 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of January 2, 2019

• Curis to Present at the 60th Annual Meeting of the American Society of Hematology

  11/20/2018

   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.

• Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

  11/7/2018

  Curis, Inc. today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting and participation in an analyst-moderated Q&A panel at Cowen's 2nd Annual IO NEXT Summit.

• Curis Reports Third Quarter 2018 Financial Results

  11/1/2018

  New leadership increasing focus on clinical execution

• Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

  10/23/2018

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.S. financial markets open.

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on October 1, 2018

  10/5/2018

  Curis, Inc. today announced that on October 1, 2018, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 30,000 shares of Curis common stock to a new employee, with a grant date of October 1, 2018 (the "Q4 2018 Inducement Grant").